Clinical trial
One Year Extension Study To Protocol C2/5/TZ:MS-05
NCT00464958 · Teva GTC, Industry · Terminated
Key facts
| NCT number | NCT00464958 |
|---|---|
| Title | One Year Extension Study To Protocol C2/5/TZ:MS-05 |
| Official title | Long Term Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in Patients With Multiple Sclerosis - Open Label Extension Study |
| Lead sponsor | Teva GTC, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Spasticity, Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | sublingual tizanidine 12 mg |
| Enrollment | 10 |
| Start date | Jan 1, 2008 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Apr 24, 2007 |
| Last update posted | Feb 19, 2009 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: